News Focus
News Focus
icon url

RioLobo

04/05/17 7:48 PM

#210481 RE: DewDiligence #210472

>Dr. Gottlieb also said that savings on biosimilars—cheaper versions of complex biologic drugs—have been disappointing. Only two such drugs have launched in the U.S. so far, with limited uptake. <<

Does MNTA account for all two?